公告提醒:爱必信所有产品和服务仅用于科学研究,不用于临床应用及其他用途提供产品和服务(也不为任何个人提供产品和服务)!
抑制剂描述:
产品名称:S3I-201
产品别名:2-羟基-4-[[2-[[(4-甲基苯基)磺酰基]氧基]乙酰基]氨基]苯甲酸
英文别名:S3I201;NSC74859;NSC 74859;NSC-74859;S3I 201
靶点:STAT3
CAS:501919-59-1
纯度:>98%
外观:white to beige Powder
保存方法:store at -20℃ for one year(Powder); in DMSO or others solvent store at 2-4℃ for two weeks, at -80℃ for six months.
描述:
S3I-201 (NSC 74859) is a Stat3 inhibitor with IC50 of 86 μM.
溶解性:DMSO :36.5 mg/mL (100 mM)
体外研究:
S3I-201选择性抑制Stat3 DNA结合活性。S3I-201抑制Stat3·Stat3复合形式,不依赖于Stat3的激活状态。S3I-201不干涉Lck SH2与同源pTyr肽结合。S3I-201作用于NIH 3T3/v-Src鼠成纤维细胞和人类乳腺癌MDA-MB-231, MDA-MB-435, 和MDA-MB-468 细胞,可以抑制Stat3激活。S3I-201 抑制Stat3依赖的转录活性。 S3I-201 也抑制编码cyclin D1, Bcl-xL,和surviving 的Stat3-调节基因的表达。S3I-201可以降低 pS727STAT3水平和降低TGF-β通路蛋白水平。S3I-201也可抑制CD133+ 和CD133− Huh-7细胞。最新研究显示S3I-201作用于Hep-G2, Huh-7和SK-HEP-1细胞,加强 Cetuximab的抗增殖效果。
体内研究:Human breast (MDA-MB-231) tumor-bearing mice are given an i.v. injection of NSC 74859 (S3I-201) or vehicle every 2 or every 3 days for 2 weeks, and tumor measurements are taken every 2-3 days. Compared with control (vehicle-treated) tumors, which continued to grow, human breast tumors in mice that received S3I-201 display strong growth inhibition. Continued evaluation of treated mice on termination of treatment shows no resumption of tumor growth, suggesting potentially a long-lasting effect of S3I-201 on tumor growth. Compared with vehicle-treated control tumors (n=15), which continued to grow, S3I-201 treatment of somatotroph tumor xenografts (n=15) significantly attenuated tumor growth for the duration of the experiment. Tumors derived from NSC 74859-treated rats are significantly smaller than those from the untreated group (220±16 mm3 vs. 287±16 mm3, P3 vs. 708±83 mm3, P.
产品信息订购:
abs810740
S3I-201
5mg
376
立即咨询
产品更多信息请进入爱必信网站咨询